Timothy N J Bullock
Overview
Explore the profile of Timothy N J Bullock including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
46
Citations
856
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Thim E, Kitelinger L, Rivera-Escalera F, Mathew A, Elliott M, Bullock T, et al.
bioRxiv
. 2023 Sep;
PMID: 37732205
Background: Boiling histotripsy (BH), a mechanical focused ultrasound ablation strategy, can elicit intriguing signatures of anti-tumor immunity. However, the influence of BH on dendritic cell function is unknown, compromising our...
12.
Conarroe C, Bullock T
Cancers (Basel)
. 2023 Jun;
15(11).
PMID: 37296865
High-grade gliomas are malignant brain tumors, and patient outcomes remain dismal despite the emergence of immunotherapies aimed at promoting tumor elimination by the immune system. A robust antitumor immune response...
13.
Gamache A, Conarroe C, Adair S, Bauer T, Padilla F, Bullock T
Front Cell Dev Biol
. 2023 May;
11:1173686.
PMID: 37123403
Immune checkpoint blockade immunotherapy has radically changed patient outcomes in multiple cancer types. Pancreatic cancer is one of the notable exceptions, being protected from immunotherapy by a variety of mechanisms,...
14.
Price R, Bullock T, Sheybani N
J Control Release
. 2022 Jul;
349:16-17.
PMID: 35780955
No abstract available.
15.
16.
Sheybani N, Witter A, Garrison W, Miller G, Price R, Bullock T
J Neurooncol
. 2021 Nov;
156(1):109-122.
PMID: 34734364
Purpose: Glioblastoma (GB) poses formidable challenges to systemic immunotherapy approaches owing to the paucity of immune infiltration and presence of the blood brain/tumor barriers (BBB/BTB). We hypothesize that BBB/BTB disruption...
17.
Bullock T
Cell Mol Immunol
. 2021 Jul;
19(1):14-22.
PMID: 34282297
The substantial advances attained by checkpoint blockade immunotherapies have driven an expansion in the approaches used to promote T cell access to the tumor microenvironment to provide targets for checkpoint...
18.
Stevens A, Bullock T
Cancer Immunol Immunother
. 2021 Jan;
70(8):2139-2150.
PMID: 33452626
Dendritic cells are potently activated by the synergistic action of CD40 stimulation in conjunction with signaling through toll like receptors, subsequently priming T cells. Cancer vaccines targeting the activation of...
19.
Seki S, Posyniak K, McCloud R, Rosen D, Fernandez-Castaneda A, Beiter R, et al.
Sci Signal
. 2020 Oct;
13(655).
PMID: 33109748
Small molecules that promote the metabolic activity of the pyruvate kinase isoform PKM2, such as TEPP-46 and DASA-58, limit tumorigenesis and inflammation. To understand how these compounds alter T cell...
20.
Duska L, Scalici J, Temkin S, Schwarz J, Crane E, Moxley K, et al.
Cancer
. 2020 Sep;
126(22):4948-4956.
PMID: 32910478
Background: Immune checkpoint inhibitors are being considered for locally advanced cervical cancer (LACC) together with standard-of-care pelvic chemoradiation (CRT). However, the safety of the combination and its optimal schedule are...